GLP-1 Market
LLY $1115.70 ▼ -0.7% NVO $43.07 ▼ -2.1% PFE $27.72 ▲ +0.3% VKTX $31.98 ▼ -0.5% KLRA $13.94 ▼ -6.5% GPCR $38.66 ▼ -2.3% RHHBY $52.82 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Teplizumab

Company
Sanofi
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
8 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

8 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 12, 2026

Find a Clinical Trial Near Me

See recruiting studies for Teplizumab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06338553

    GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

    Not yet reported Vanderbilt University Medical Center 24 participants Est. completion 2027-03 1 site Added to GLP-1
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Recruiting NCT NCT06481904

    Registry for Stage 2 Type 1 Diabetes

    Sanofi 200 participants Est. completion 2037-01-15 37 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Recruiting NCT NCT06791291

    Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

    Not yet reported Sanofi 10 participants Est. completion 2028-03-06 11 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07088068

    A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

    Not yet reported Sanofi 723 participants Est. completion 2028-12-12 164 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07216391

    Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 60 participants Est. completion 2030-05-30 6 sites
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07260110

    A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

    Sanofi 550 participants Est. completion 2030-12-03 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Recruiting NCT NCT07360080

    Long-Term Outcomes of Teplizumab in Routine Clinical Care

    Sanofi 1000 participants Est. completion 2035-10-29 10 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Recruiting NCT NCT07457580

    Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

    Sanofi 60 participants Est. completion 2026-11-30 14 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Status unknown NCT NCT00008801

    hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure

    Not yet reported, Not yet reported National Center for Research Resources (NCRR) 1 site
    Other conditions: Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental, Transplantation, Homologous, Islets of Langerhans Transplantation
    View official trial listing →
  • Completed NCT NCT00129259

    Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 83 participants Est. completion 2011-03 7 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Terminated NCT NCT00239720

    PsA Treatment With hOKT3γ1 (Ala-Ala)

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 4 participants Est. completion 2008-06-25 2 sites
    Other conditions: Arthritis, Psoriatic
    View official trial listing →
  • Completed NCT NCT00378508

    Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

    Not yet reported Yale University 63 participants Est. completion 2013-08 4 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00385697

    The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

    Not yet reported, Not yet reported MacroGenics 554 participants Est. completion 2011-08 115 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT00806572

    Treatment With hOKT3gamma1(Ala-Ala) in T1DM

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 10 participants Est. completion 2007-08 3 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Terminated NCT NCT00870818

    Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

    Not yet reported MacroGenics 219 participants Est. completion 2011-05 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT00920582

    Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

    Not yet reported MacroGenics 254 participants Est. completion 2012-07 118 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT00954915

    Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

    Not yet reported, Not yet reported MacroGenics 1 participants Est. completion 2010-07 2 sites Stand-alone
    Other conditions: Psoriasis
    View official trial listing →
  • Completed NCT NCT01030861

    Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 76 participants Est. completion 2019-06 19 sites
    Prediabetes Other conditions: Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk
    View official trial listing →
  • Terminated NCT NCT01189422

    Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes

    Not yet reported MacroGenics 1 participants Est. completion 2011-02 Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02067923

    AbATE Follow-Up Study

    Yale University 44 participants Est. completion 2016-11-17 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03751007

    A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

    Not yet reported, Not yet reported Precigen Actobio T1D, LLC 45 participants Est. completion 2021-10-13 18 sites Stand-alone
    Other conditions: Diabetes type1
    View official trial listing →
  • Completed NCT NCT03875729

    Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

    Not yet reported Provention Bio, Inc. 328 participants Est. completion 2023-05-01 62 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04270942

    At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

    Not yet reported Provention Bio, a Sanofi Company 6 participants Est. completion 2024-01-22 8 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Active, not recruiting NCT NCT04598893

    Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

    Provention Bio, a Sanofi Company 188 participants Est. completion 2026-11 47 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Active, not recruiting NCT NCT05757713

    Teplizumab in Pediatric Stage 2 Type 1 Diabetes

    Not yet reported Sanofi 20 participants Est. completion 2026-08-27 10 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT06892002

    Description of Patients With Type 1 Diabetes Treated With Teplizumab

    Sanofi 110 participants Est. completion 2025-08-05 27 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07610213

    Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes

    Not yet reported Abdullah Kars 60 participants Est. completion 2030-06-01 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus (T1DM), Type 1 Diabetes Mellitus, Autoimmune Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Teplizumab, TZIELD, SAR446681

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.